ReviewFrontiers in immunology2026
CX3CR1 and CCR2: dynamic myeloid cell states across inflammatory diseases with implications for oral health and disease.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A method for distinguishing and separating retinal microglia from infiltrating macrophages during an ocular inflammatory event.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemokine receptor-mediated immune cell trafficking is a fundamental determinant of inflammatory disease outcomes. Among chemokine receptors, CCR2 and CX3CR1 represent two functionally distinct but interconnected axes that regulate inflammatory monocyte recruitment and tissue macrophage retention, respectively. However, emerging evidence suggests that these receptors function as dynamic regulators of context-dependent myeloid cell states rather than fixed markers of discrete immune cell subsets. A central focus of this review is the recruitment-to-residency axis, which describes the functional transition of myeloid cells from inflammatory recruitment to tissue adaptation during chronic inflammation. In acute inflammation, CCR2-dependent recruitment is often essential for host defense and tissue repair; however, sustained CCR2 signaling promotes chronic inflammation and tissue damage. Conversely, CX3CR1 signaling maintains homeostasis under steady-state conditions, but can contribute to disease chronicity by retaining pathogenic macrophage populations within tissues. In this review, we summarize the cellular sources and regulatory mechanisms of CX3CR1 and CCR2, discuss their context-dependent roles across neurological, cardiovascular, mucosal, metabolic, fibrotic, and infectious diseases, and propose a unifying recruitment-to-residency axis. We further discuss periodontitis as a representative chronic inflammatory disease in which dysregulated CCR2-CX3CR1 dynamics may contribute to persistent inflammatory macrophage accumulation and osteoclastogenic tissue destruction. Understanding the dynamic interplay between CX3CR1 and CCR2 provides a conceptual framework for precision immunomodulatory strategies targeting the transition points of chronic inflammatory diseases, including those affecting oral health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.